QUOFENIX 300 mg, powder for concentrate for infusion 10 bottles of 20 ml
Active ingredients: DÉLAFLOXACINE, DÉLAFLOXACINE MÉGLUMINE
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Powder for concentrate for infusion10 bottles of 20 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- QUOFENIX 300 mg, poudre pour solution à diluer pour perfusion
- Pharmaceutical form
- poudre pour solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 10 flacon(s) en verre de 20 ml
- Marketing authorisation holder
- MENARINI ITALIE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 28 Jun 2021
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Hospital use only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69148567CIP75507219CIP133400955072195Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| DÉLAFLOXACINEpoudre | 300 mg · un flacon | FT |
| DÉLAFLOXACINE MÉGLUMINEpoudre | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.